CLCM
DNLI icon

Crawford Lake Capital Management’s Denali Therapeutics DNLI Stock Holding History

Crawford Lake Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-38,726
Closed -$1.39M – 64
2020
Q3 		$1.39M Buy
+38,726
New +$1.17M 0.58% 44

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crawford Lake Capital Management's DNLI Position: Q4 2020 in Review

Crawford Lake Capital Management sold out of Denali Therapeutics (DNLI) in Q4 2020, closing a stake of 38,726 shares — an estimated $1.39M sold.

Crawford Lake Capital Management first reported a position in DNLI in Q3 2020 and held it in 1 quarter. The position peaked at $1.39M in Q3 2020. 204 funds tracked by Wall St. Rank hold DNLI as of Q4 2020.

  • Crawford Lake Capital Management reported no remaining Denali Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Crawford Lake Capital Management sold 38,726 Denali Therapeutics shares in Q4 2020, an estimated $1.39M.
  • Crawford Lake Capital Management first reported a position in Denali Therapeutics in Q3 2020 and held it in 1 quarter.
  • Crawford Lake Capital Management's Denali Therapeutics position peaked at $1.39M in Q3 2020.
  • 204 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2020.

Based on Crawford Lake Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.